Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemia

Science Signaling
Chelsea JenkinsJeffrey W Tyner

Abstract

The protein tyrosine phosphatase PTPN11 is implicated in the pathogenesis of juvenile myelomonocytic leukemia (JMML), acute myeloid leukemia (AML), and other malignancies. Activating mutations in PTPN11 increase downstream proliferative signaling and cell survival. We investigated the signaling upstream of PTPN11 in JMML and AML cells and found that PTPN11 was activated by the nonreceptor tyrosine/serine/threonine kinase TNK2 and that PTPN11-mutant JMML and AML cells were sensitive to TNK2 inhibition. In cultured human cell-based assays, PTPN11 and TNK2 interacted directly, enabling TNK2 to phosphorylate PTPN11, which subsequently dephosphorylated TNK2 in a negative feedback loop. Mutations in PTPN11 did not affect this physical interaction but increased the basal activity of PTPN11 such that TNK2-mediated activation was additive. Consequently, coexpression of TNK2 and mutant PTPN11 synergistically increased mitogen-activated protein kinase (MAPK) signaling and enhanced colony formation in bone marrow cells from mice. Chemical inhibition of TNK2 blocked MAPK signaling and colony formation in vitro and decreased disease burden in a patient with PTPN11-mutant JMML who was treated with the multikinase (including TNK2) inhibitor da...Continue Reading

References

Jan 20, 2005·Molecular & Cellular Proteomics : MCP·April ThelemannJohn D Haley
Oct 26, 2005·Proceedings of the National Academy of Sciences of the United States of America·Edward Htun van der HorstScott Powers
May 15, 2007·Proceedings of the National Academy of Sciences of the United States of America·Nupam P MahajanYoung E Whang
Feb 12, 2008·Experimental Cell Research·Lene Melsaether GrøvdalEspen Stang
Feb 21, 2008·Cancer Metastasis Reviews·Gordon ChanBenjamin G Neel
Sep 17, 2008·Nature Structural & Molecular Biology·Mohammad AzamGeorge Q Daley
May 13, 2009·Proceedings of the National Academy of Sciences of the United States of America·Jeffrey W TynerBrian J Druker
May 20, 2009·Bioinformatics·Heng Li, Richard Durbin
Jan 30, 2010·The Journal of Biological Chemistry·Victoria Prieto-EchagüeW Todd Miller
Feb 12, 2011·The Biochemical Journal·Wing ChanEd Manser
Nov 1, 2011·Nature Biotechnology·Mindy I DavisPatrick P Zarrinkar
Dec 12, 2012·The Journal of Clinical Investigation·Tiffany ChangKevin Shannon
Feb 12, 2013·Nature Biotechnology·Kristian CibulskisGad Getz
Apr 6, 2013·Nucleic Acids Research·Yang LiaoWei Shi
May 3, 2013·The New England Journal of Medicine·UNKNOWN Cancer Genome Atlas Research NetworkGreg Eley
May 10, 2013·The New England Journal of Medicine·Julia E MaxsonJeffrey W Tyner
Feb 1, 2014·Carcinogenesis·Valentina E SchneebergerJie Wu
Aug 27, 2014·Proceedings of the National Academy of Sciences of the United States of America·Severa BundaMichael Ohh
Sep 16, 2014·Acta Pharmacologica Sinica·Rong-Jun HeZhong-Yin Zhang
Jan 7, 2015·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Oct 13, 2015·Nature Genetics·Elliot StieglitzMignon L Loh
Dec 1, 2015·Nature Communications·Severa BundaMichael Ohh
Mar 2, 2016·Proceedings of the National Academy of Sciences of the United States of America·Raven J ReddyForest M White
Jun 28, 2016·Journal of Medicinal Chemistry·Jorge Garcia FortanetMatthew J LaMarche
Oct 7, 2016·Nature·Jeffrey Perkel
Dec 13, 2016·JCI Insight·Jae-Sung YiAnton M Bennett
Aug 9, 2017·Proceedings of the National Academy of Sciences of the United States of America·Stephen E KurtzJeffrey W Tyner

❮ Previous
Next ❯

Citations

Jan 15, 2020·Journal of Cancer Research and Clinical Oncology·Nicole KiwelerOliver H Krämer
Apr 17, 2021·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·J JianB Liu
Sep 11, 2021·Nature Communications·Tsz-Yin ChanJoshua L Andersen

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.